Can India become the pharmacy for weight-loss drugs?

In today’s episode on 26th March 2026, we tell you whether India can truly become the world’s largest exporter of affordable GLP-1 medicines, better known as weight-loss drugs. Book a FREE call with Ditto https://ditto.sh/vx51ji

• 0:00Speaker 00

  Hello folks, you're tuned into Finchart's Daily. In today's episode, we tell you whether India can truly become the world's largest exporter of affordable GLP-1 medicines, better known as weight loss drugs.

• 0:15Speaker 00

  But here's a quick disclaimer before we begin. The story is about affordable weight loss drugs and there's a lot of excitement around them, but don't let the online buzz influence you to take any medication on your own. Please consult a qualified doctor before doing so. Alright. The last time we wrote about affordable diabetes and weight loss drugs, about a year ago, we told you that a drug revolution would arrive in 2026. Turns out, it may just have begun. Last weekend, a key patent on semaglutide, the molecule behind Danish drug maker Nouradis' popular drugs Wegovy and Ozempic, expired in India. And almost immediately, a B-line of drug makers lined up to launch generics, that's identical medicines sold at lower prices.

• 1:00Speaker 00

  And that, as you may have already heard, could mean that cheaper versions of semaglutide are on their way, transforming access to diabetes and weight loss treatment in India. For context, Nouradis' semaglutide drugs can cost around 8,800 to 10,000 rupees per month. Generics, on the contrary, could be priced up to 60% lower, making them far more affordable. And that's no small deal in a country like India, where nearly 10 crore people live with diabetes and a significant share also struggle with obesity. Now, before we go any further into the story, we'd like to give you a quick background on how these medicines work. Look, when you eat carbohydrates like rice, roti, bread, etc., your digestive system breaks

• 1:42Speaker 00

  them down into glucose, which is a type of sugar that floods your bloodstream. As this happens, the cells in your gut release a natural hormone called GLP-1, that is glucagon like peptide 1. The smart signal does three jobs at once. First, it tells the pancreas to release insulin, a hormone that acts like a delivery truck, transporting glucose into muscle cells and other tissues for energy. But only when blood sugar is actually high, avoiding Crashes. Second, it slows digestion, so sugar enters the blood gradually, so as to not spike it. Third, it travels to the brain, tiling down hunger and signaling you're full. But in diabetic patients, particularly type 2 diabetes, this turns out into something of a chaos.

• 2:26Speaker 00

  Cells start ignoring insulin's signal called insulin resistance, glucose piles up and the pancreas work overtime until it can't keep up. And that ends up pushing blood sugar levels higher, paving the way for other health issues over time. To fix this, scientists tried to replicate the natural GLP-1 system in the lab, creating semaglutide, a type of GLP-1 receptor agonist. These drugs mimic the hormones' effects, but better and longer. But during trials, scientists also realized that it didn't just control blood sugar, it actually led to significant weight loss as well. And that's when semaglutide drugs began to be used, not just for treating diabetes, but for tackling obesity too.

• 3:06Speaker 00

  Which brings us to India. After the patent on this popular diabetes and weight loss drug expired, pharma giants aren't just targeting the domestic market anymore. Their eyes are firmly on exports too, planning to scale up and ship these cheaper drugs to countries where no nordisks semaglutide patents have also expired this year, like Canada, Turkey and Brazil. And you can see why. Together, these countries account for roughly thirty percent of the world's population and nearly the same share of adults living with obesity. That's a massive opportunity, especially for a country like India, often called the world's pharmacy with its well-developed generics industry supplying around twenty percent of global off-patent medicines.

• 3:43Speaker 00

  But here's the thing, India may be generic king when it comes to pills, tablets and capsules, but the most visible face of Wegovy and Zumpick generics is in a pill, it's an injectable pen. This is essentially a glass cartridge filled with the drug solution, tucked inside a sleek reusable plastic device roughly the size of a TV remote. It comes with a hidden needle as thin as one or two strands of human hair and a dose dial. You simply press to inject with DozeMendose, even for the visually impaired. Sure, pills exist, but the injectable pen has been the real workhorse. It delivers the drug efficiently, works at lower doses, lasts longer in body and is so easy to use that you barely feel a thing. Wiles with separate syringes are cheaper, no doubt, but they can be tricky to handle, especially for older patients.

• 4:28Speaker 00

  And that's why both patients and doctors tend to prefer pens in obesity care. Which means if India is eyeing that big export opportunity, hoping to become the world's largest supplier of affordable weight loss drugs, the road ahead won't be easy. The main challenge being making these drug delivery devices, the pre-filled pens themselves, they need precision engineered plastics, glass cartridges, ultrafine needles, springs and dose mechanisms that can reliably deliver small variable doses every week. Now, India does have experience with syringes and some insulin pens, but when it comes to high-end components, especially pen systems for complex biologics, a significant share has historically been imported. Needles often come from Japan, glass from Germany and pens from Switzerland.

• 5:12Speaker 00

  And then there's another problem that walks in. These drugs need to be assembled in clean environments, tested mechanically and then shipped through a cold chain that must maintain two to eight degrees centigrade all the way from factory to pharmacy. Sure, India's cold chain has improved rapidly over the years, but it's still patchy. It's probably good enough to support large-scale GLP-1 exports to many markets, but not yet strong or uniform enough to call it a full-ready dominant world exporter infrastructure. That said, things are changing. After COVID, investments in biologics, vaccines and injectables have significantly expanded cold chain capacity across the Asia-Pacific region, with India emerging as one of the fastest-growing markets through 2030.

• 5:52Speaker 00

  Production-linked incentives or PLIs are driving new compliant warehouses and while handling hubs around pharma clusters like Hyderabad, Ahmedabad and Pune, specifically to support biologics and injectable exports. On top of that, cold chain logistics have seen upgrades like GPS-enabled refill trucks and retrofitted warehouses with full backup power, all designed around pharma's needs. But you have to understand that when it comes specifically to GLP-1 drugs, things get a bit more nuanced. Cold chain storage is still limited across India, especially beyond major metro cities, and that could become a real bottleneck. Because as demand for These cheaper drugs rises, storing and distributing peptide injectables like semaglutide at scale won't be easy.

• 6:36Speaker 00

  To give you a sense of scale, India's GLP-1 market is expected to grow rapidly with demand for diabetes and weight management therapies potentially multiplying fivefold by 2030. And globally, the market is expected to expand at a similar pace. But the problem is that the complexity of manufacturing GLP-1 drugs and delivering them through devices like pens is already starting to strain existing supply chains. So whether India becomes the world's pharmacy for cheap weight loss drugs will depend on the choices it makes now. Like whether it treats GLP-1s as just another generic molecule or as a once in a generation opportunity to build a full stack industry can handle molecules, devices and cold chains together. Because otherwise, it risks losing ground to China, where semaglutide patents have also expired last week.

• 7:19Speaker 00

  Besides, China also already has a crowded pipeline of late-stage semaglutide programs alongside strong capabilities and drug delivery devices and vertically integrated factories that can take production from peptides all the way up to pens for export. And if that happens, India's price advantage may not count for much in the weight loss drug race after all. All right, folks, I'll see you in the next one. Thank you for listening to today's episode. And if you want to share your feedback or suggestions, do drop us an email to [email protected]. Until next time.